CG
PTGX icon

Caprock Group’s Protagonist Therapeutics PTGX Stock Holding History

Caprock Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$455K Buy
+3,712
New +$388K 0.01% 884
2026
Q1 		– Sell
-5,991
Closed -$523K – 1258
2025
Q4 		$523K Buy
5,991
+189
+3% +$15.5K 0.01% 803
2025
Q3 		$343K Buy
+5,802
New +$330K 0.01% 907
2025
Q1 		$285K Buy
5,890
+88
+2% +$3.69K 0.01% 885
2024
Q4 		$224K Buy
+5,802
New +$253K 0.01% 906

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Caprock Group's PTGX Position: Q2 2026 in Review

Caprock Group opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 3,712 shares worth $455K. The stake represents 0.01% of the portfolio and ranks #884 among its holdings. This is a return to the name: Caprock Group previously reported a position in PTGX as recently as Q4 2025.

Caprock Group first reported a position in PTGX in Q4 2024 and has held it in 5 quarters since. The position peaked at $523K in Q4 2025. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Caprock Group held 3,712 shares of Protagonist Therapeutics worth $455K as of Q2 2026.
  • Protagonist Therapeutics was a new Caprock Group position in Q2 2026.
  • Protagonist Therapeutics made up 0.01% of Caprock Group's portfolio in Q2 2026, its #884 holding.
  • Caprock Group first reported a position in Protagonist Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Caprock Group's Protagonist Therapeutics position peaked at $523K in Q4 2025.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Caprock Group's 13F filing for Q2 2026, filed 27 Jul 2026.